



US009546991B2

(12) **United States Patent**  
**Li et al.**

(10) **Patent No.:** **US 9,546,991 B2**  
(45) **Date of Patent:** **Jan. 17, 2017**

(54) **SYSTEM FOR THE CONCOMITANT ASSESSMENT OF DRUG DISSOLUTION, ABSORPTION AND PERMEATION AND METHODS OF USING THE SAME**

G01N 2001/4016; G01N 33/15; G01N 13/00; G01N 13/15; G01N 13/5082; G01N 13/5008; B01D 63/087; B01D 69/10; B01D 6/28

See application file for complete search history.

(71) Applicant: **Absorption Systems Group, LLC**,  
Exton, PA (US)

(56) **References Cited**

(72) Inventors: **Jibin Li**, West Chester, PA (US);  
**Ismael J. Hidalgo**, Exton, PA (US)

U.S. PATENT DOCUMENTS

(73) Assignee: **Absorption Systems Group, LLC**,  
Exton, PA (US)

3,749,646 A \* 7/1973 Pirt ..... C12M 23/08  
210/321.84  
3,802,272 A \* 4/1974 Bischoff ..... G01N 13/00  
366/142

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(Continued)

(21) Appl. No.: **14/946,998**

FOREIGN PATENT DOCUMENTS

(22) Filed: **Nov. 20, 2015**

WO WO 96/02627 A1 2/1996  
WO WO 97/16717 A1 5/1997

(Continued)

(65) **Prior Publication Data**

US 2016/0146774 A1 May 26, 2016

OTHER PUBLICATIONS

"The Dissolution Procedure: Development and Validation", The United States Pharmacopeial Convention, May 2012, Chapter USP 35, 675-681.

(Continued)

**Related U.S. Application Data**

(60) Provisional application No. 62/082,738, filed on Nov. 21, 2014.

*Primary Examiner* — William H Beisner

(74) *Attorney, Agent, or Firm* — Baker & Hostetler LLP

(51) **Int. Cl.**  
**C12M 1/34** (2006.01)  
**G01N 33/15** (2006.01)

(Continued)

(52) **U.S. Cl.**  
CPC ..... **G01N 33/15** (2013.01); **G01N 13/00**  
(2013.01); **G01N 33/5008** (2013.01);  
(Continued)

(58) **Field of Classification Search**  
CPC ..... C12M 25/02; C12M 25/04; C12M 21/08;  
C12M 23/06; C12M 25/14; C12M 27/02;  
G01N 15/0806; G01N 2015/086; G01N  
2013/00; G01N 2013/003; G01N  
2013/006; G01N 13/04; G01N 1/4005;

(57) **ABSTRACT**

Disclosed herein are devices for assessing drug dissolution, absorption and permeation, the devices comprising a chamber, a permeability barrier, and a securing cap, each in fluid communication with each other. The chamber comprises a reservoir and an extension. The permeability barrier is configured to hold cells, tissues, or artificial membranes, and the securing cap is configured to reversibly attach to the permeability barrier or the extension of the chamber. Also provided are systems for assessing drug dissolution, absorption and permeation, the systems comprising at least one of the devices for assessing drug dissolution, absorption and permeation, a dissolution vessel configured to hold a disso-

(Continued)

